Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Nanoconjugados formados por moléculas dendríticas y péptidos como agentes antitumorales contra el cáncer de próstata avanzado

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20181015003
Publicado:
02/11/2018
Caducidad:
03/11/2019
Resumen:
Un grupo de investigación de una universidad española ofrece una nueva invención que se refiere a la formación de nanoconjugados con actividad antitumoral, principalmente contra el cáncer de próstata avanzado. La formación de los nanoconjugados se realiza mezclando en disolución, preferiblemente acuosa en presencia o ausencia de tampón, las moléculas dendríticas y péptidos correspondientes. Estos sistemas están formados por moléculas dendríticas (dendrímeros y dendrones) y neuropéptidos. Preferentemente, las macromoléculas dendríticas son de estructura carbosilano, principalmente con funciones catiónicas en la periferia, y los neuropéptidos son de la familia glucagón/secretina, principalmente VIP, GHRH y PACAP. El grupo de investigación busca empresas y centros de investigación de los sectores biomédico, farmacéutico y sanitario con el fin de establecer acuerdos de licencia, cooperación o comercialización con asistencia técnica.

Details

Tittle:
Nanoconjugates formed by dendritic molecules and peptides as antitumor agents against advanced prostate cancer.
Summary:
A Research Group of a Spanish university presents a new invention that refers to the formation of nanoconjugates with antitumor activity, mainly against advanced prostate cancer. The research group seeks companies and research institutions from the Biomedicine, Pharmaceutical, and Health sector, to establish licensing agreements, cooperation agreements or commercial agreements with technical assistance.
Description:
The spanish research group presents an invention focused on the preparation of active nanoconjugates against advanced prostate cancer and to prevent metastasis.
The formation of the nanoconjugates is carried out by mixing in solution, preferably aqueous in the presence or absence of buffer, the dendritic molecules and the corresponding peptides.
These systems are formed by dendritic molecules (dendrimers and dendrons) and neuropeptides. Preferably, the dendritic macromolecules are of carbosilane structure, mainly with cationic functions in the periphery, and the neuropeptides are of the glucagon / secretin family, mainly VIP, GHRH and PACAP. These nanoconjugates are formed by combining the dendritic molecule and the corresponding peptide in the necessary proportion.
The present invention also relates to the biomedical uses of the peptide / dendritic molecule combinations.
Preferably this invention is for the development of drugs for the treatment of prostate cancer. However, other types of cancers are not excluded. Examples of pharmaceutical preparations include any solid composition (tablets, pills, capsules, granules, etc.) or liquid (gels, solutions, suspensions or emulsions) for oral, nasal, topical or parenteral administration.
The research group seeks for companies and research institutions from the Biomedicine, Pharmaceutical and Health sector, to establish licensing agreements, cooperation agreements or commercial agreements with technical assistance.
Advantages and Innovations:
- The properties of nanoconjugates allow treating tumor cells when they have already invaded the area of the gland (prostate).
- Both dendrimers and dendrons allow concentrating a large number of functional groups producing a unique effect, different from that could be find in these same groups if they were acting individually.
- The main application of the patented compounds lies in their antitumor activity, preferably against advanced prostate cancer.
- Dendritic systems can be used as transporters of drugs or antitumor nucleic acids due to their ability to be absorbed "in vivo" in tumor zones and to internalize the treatment in cancer cells.
- The dendrimer also remains in the tumor zone without returning to the bloodstream.
- The necessary development, for the commercial exploitation of this patent, does not entail a high technical difficulty.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
The patent has been requested to the OEPM with reference P201700069.
Nothing similar has been found in patent databases or in the scientific literature consulted.

Partner sought

Type and Role of Partner Sought:
The research group seeks for companies and research institutions from the Biomedicine, Pharmaceutical and Health sector, to establish licensing agreements, cooperation agreements or commercial agreements with technical assistance.

Companies are sought preferably to exploit the results of this invention via commercial agreements with technical assistance and licensing agreements.

Research institutions and companies with a solid R-Y-D background are sought to foster the technology one step forward through cooperation agreements.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001005 Diagnósticos, diagnosis